Browsing College of Medicine by Subject "HER2"

Now showing items 1-5 of 5

    • 2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina. 

      Bešlija, Semir; Gojković, Zdenka; Cerić, Timur; Mekić Abazović, Alma; Marijanović, Inga; ... more authors ( Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina , 2020 , Article)
      The HERe2cure project, which involved a group of breast cancer experts, members of multidisciplinary tumor boards from healthcare institutions in Bosnia and Herzegovina, was initiated with the aim of defining an optimal ...

    • Apocrine Carcinoma 

      Vranic, Semir; Gatalica, Zoran ( Springer, Cham , 2017 , Book chapter)
      Carcinoma with apocrine differentiation (invasive apocrine carcinoma) is defined by “WHO Classification of Tumours of the Breast” as “any invasive carcinoma in which cells show the cytological features of apocrine cells” ...

    • Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models. 

      Padmanabhan, Regina; Kheraldine, Hadeel Shafeeq; Meskin, Nader; Vranic, Semir; Al Moustafa, Ala-Eddin ( Springer , 2020 , Article)
      Breast cancer is one of the major causes of mortality in women worldwide. The most aggressive breast cancer subtypes are human epidermal growth factor receptor-positive (HER2) and triple-negative breast cancers. Therapies ...

    • HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome. 

      Skenderi, Faruk; Alahmad, Mohamad Alhoda Mohamad; Tahirovic, Emin; Alahmad, Yaman M; Gatalica, Zoran; ... more authors ( Springer , 2022 , Other)
      Apocrine carcinoma of the breast (APO) expresses HER2 in 30-50% of cases. This study explored the clinicopathological features and outcome of HER2+/APO and matched HER2+/NST cohort. We used the SEER database to explore the ...

    • Quantification of the growth suppression of HER2+ breast cancer colonies under the effect of trastuzumab and PD-1/PD-L1 inhibitor. 

      Padmanabhan, Regina; Kheraldine, Hadeel; Gupta, Ishita; Meskin, Nader; Hamad, Anas; ... more authors ( Frontiers Media , 2022 , Article)
      Immune checkpoint blockade (ICB)-based therapy is revolutionizing cancer treatment by fostering successful immune surveillance and effector cell responses against various types of cancers. However, patients with HER2+ ...